2022 World Conference on Lung Cancer (Posters)-P2.12-04. The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)

P2.12-04. The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)

Back to course

Pdf Summary

A study was conducted to investigate the role of a blood-based proteomic test, called VeriStrat, in predicting survival in patients with non-small cell lung cancer (NSCLC) who have low levels of PD-L1 expression and are receiving immune checkpoint inhibitor (ICI) treatment. The VeriStrat test uses machine learning and mass spectrometry to generate a proteomic signature. Previous studies have shown that the VeriStrat test can predict patient outcomes in different stages, histologies, and treatment types of NSCLC. However, its utility in patients with low PD-L1 expression and limited response to ICI treatment is not well-established.<br /><br />The retrospective study included 61 patients with advanced stage NSCLC who received either ICI monotherapy or combination therapy with PD-L1 expression of 50% or less. Blood samples were collected from these patients between 2016 and 2021, and VeriStrat testing was performed. Patients were categorized into two groups based on their VeriStrat test results: VeriStrat 'Good' (VS-G) or VeriStrat 'Poor' (VS-P). Overall survival (OS) and progression-free survival (PFS) were calculated and compared between the two groups.<br /><br />The results showed that patients in the VS-G group had better PFS and OS compared to those in the VS-P group. Among patients with negative PD-L1 expression, the VS-G group had significantly longer PFS compared to the VS-P group, although no significant difference was found in OS. Among patients with low PD-L1 expression, superior OS was observed in the VS-G group compared to the VS-P group, with no significant difference in PFS. In patients who received ICI monotherapy, better OS was observed in the VS-G group compared to the VS-P group, while PFS was similar between the two groups. No significant differences in OS and PFS were observed in patients who received ICI and chemotherapy combination.<br /><br />These findings suggest that the VeriStrat test can predict PFS and OS in NSCLC patients with low or negative PD-L1 expression receiving ICI treatment. Patients with a 'Good' VeriStrat status had better survival outcomes compared to those with a 'Poor' VeriStrat status. This blood-based proteomic signature could potentially be used as a predictive biomarker for personalized treatment decisions in this patient population. Further studies are warranted to validate these findings.

Asset Subtitle

Youjin Oh, United States

Meta Tag

Speaker Youjin Oh, United States

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

blood-based proteomic test

VeriStrat

survival prediction

non-small cell lung cancer

NSCLC

PD-L1 expression

immune checkpoint inhibitor

machine learning

mass spectrometry

proteomic signature